Form 4: Amneal Pharmaceuticals Director Equity Transaction

Director John Kiely acquired 34,819 shares of Amneal Pharmaceuticals through the vesting of restricted stock units.

Summary

• Director John Kiely exercised and converted 34,819 restricted stock units (RSUs) into Class A Common Stock on May 7, 2026.
• The reporting person was granted 19,824 new restricted stock units on May 6, 2026.
• Following these transactions, the director holds a total of 260,252 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it reflects routine director compensation and equity vesting rather than a change in company strategy or financial performance.

Positives

• Director maintains a significant equity stake of 260,252 shares, aligning interests with shareholders.

Negatives

• None identified; this is a standard equity compensation disclosure.

Risks

• None identified; this is a routine administrative filing regarding director compensation.

Future Outlook

The newly granted 19,824 restricted stock units are scheduled to vest on the later of the day preceding the first annual meeting of stockholders following the grant date or the first anniversary of the grant date.

Industry Context

StockSavvy.ai notes that this filing represents standard executive compensation practices within the pharmaceutical sector, where equity-based incentives are commonly used to retain board members.

Comparison to Industry Standards

• The use of RSU vesting as a component of director compensation is consistent with standard corporate governance practices for mid-cap pharmaceutical companies like Amneal Pharmaceuticals.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation event.

Next Steps

• Vesting of the 19,824 restricted stock units granted on May 6, 2026, subject to the terms of the grant.

Key Dates

Keywords

Amneal Pharmaceuticals, AMRX, Form 4, Insider Trading, Equity Compensation, Director Ownership